CELLULARLINE SPA (CELL.MI) Stock Fundamental Analysis
Europe - BIT:CELL - IT0005244618 - Common Stock
2.54 EUR
-0.01 (-0.39%)
CELL gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 30 industry peers in the Technology Hardware, Storage & Peripherals industry. CELL has an excellent financial health rating, but there are some minor concerns on its profitability. CELL is cheap, but on the other hand it scores bad on growth.
1. Profitability
1.1 Basic Checks
In the past year CELL was profitable.
CELL had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: CELL reported negative net income in multiple years.
Each year in the past 5 years CELL had a positive operating cash flow.
1.2 Ratios
CELL has a Return On Assets of 2.60%. This is comparable to the rest of the industry: CELL outperforms 56.67% of its industry peers.
CELL has a better Return On Equity (4.27%) than 63.33% of its industry peers.
With a Return On Invested Capital value of 4.42%, CELL perfoms like the industry average, outperforming 50.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.6% | ||
| ROE | 4.27% | ||
| ROIC | 4.42% |
ROA(3y)-10.28%
ROA(5y)-5.5%
ROE(3y)-16.94%
ROE(5y)-9.21%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
CELL has a Profit Margin (3.44%) which is comparable to the rest of the industry.
In the last couple of years the Profit Margin of CELL has declined.
The Operating Margin of CELL (4.91%) is comparable to the rest of the industry.
CELL's Operating Margin has declined in the last couple of years.
CELL's Gross Margin of 40.07% is fine compared to the rest of the industry. CELL outperforms 70.00% of its industry peers.
CELL's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 4.91% | ||
| PM (TTM) | 3.44% | ||
| GM | 40.07% |
OM growth 3Y35.04%
OM growth 5Y-19.56%
PM growth 3YN/A
PM growth 5Y-23.32%
GM growth 3Y-2.78%
GM growth 5Y-2.73%
2. Health
2.1 Basic Checks
CELL has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
The number of shares outstanding for CELL has been reduced compared to 1 year ago.
Compared to 5 years ago, CELL has less shares outstanding
Compared to 1 year ago, CELL has an improved debt to assets ratio.
2.2 Solvency
CELL has an Altman-Z score of 2.34. This is not the best score and indicates that CELL is in the grey zone with still only limited risk for bankruptcy at the moment.
CELL has a Altman-Z score of 2.34. This is in the better half of the industry: CELL outperforms 66.67% of its industry peers.
CELL has a debt to FCF ratio of 2.46. This is a good value and a sign of high solvency as CELL would need 2.46 years to pay back of all of its debts.
CELL has a Debt to FCF ratio of 2.46. This is in the better half of the industry: CELL outperforms 73.33% of its industry peers.
A Debt/Equity ratio of 0.13 indicates that CELL is not too dependend on debt financing.
With an excellent Debt to Equity ratio value of 0.13, CELL belongs to the best of the industry, outperforming 86.67% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.13 | ||
| Debt/FCF | 2.46 | ||
| Altman-Z | 2.34 |
ROIC/WACC0.5
WACC8.75%
2.3 Liquidity
CELL has a Current Ratio of 2.12. This indicates that CELL is financially healthy and has no problem in meeting its short term obligations.
CELL has a better Current ratio (2.12) than 66.67% of its industry peers.
A Quick Ratio of 1.33 indicates that CELL should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.33, CELL is in the better half of the industry, outperforming 70.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.12 | ||
| Quick Ratio | 1.33 |
3. Growth
3.1 Past
CELL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 60.78%, which is quite impressive.
Measured over the past years, CELL shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -20.43% on average per year.
CELL shows a small growth in Revenue. In the last year, the Revenue has grown by 3.54%.
Measured over the past years, CELL shows a small growth in Revenue. The Revenue has been growing by 3.18% on average per year.
EPS 1Y (TTM)60.78%
EPS 3YN/A
EPS 5Y-20.43%
EPS Q2Q%-4.76%
Revenue 1Y (TTM)3.54%
Revenue growth 3Y14.1%
Revenue growth 5Y3.18%
Sales Q2Q%-2.91%
3.2 Future
CELL is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 2.47% yearly.
CELL is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -0.60% yearly.
EPS Next Y-12.5%
EPS Next 2Y2.47%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-5.69%
Revenue Next 2Y-0.6%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 9.77, the valuation of CELL can be described as reasonable.
Compared to the rest of the industry, the Price/Earnings ratio of CELL indicates a rather cheap valuation: CELL is cheaper than 90.00% of the companies listed in the same industry.
The average S&P500 Price/Earnings ratio is at 25.89. CELL is valued rather cheaply when compared to this.
With a Price/Forward Earnings ratio of 5.93, the valuation of CELL can be described as very cheap.
96.67% of the companies in the same industry are more expensive than CELL, based on the Price/Forward Earnings ratio.
CELL is valuated cheaply when we compare the Price/Forward Earnings ratio to 34.59, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.77 | ||
| Fwd PE | 5.93 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, CELL is valued cheaper than 93.33% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, CELL is valued cheaper than 96.67% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 3.72 | ||
| EV/EBITDA | 2.97 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y2.47%
EPS Next 3YN/A
5. Dividend
5.1 Amount
CELL has a Yearly Dividend Yield of 3.69%. Purely for dividend investing, there may be better candidates out there.
CELL's Dividend Yield is rather good when compared to the industry average which is at 1.97. CELL pays more dividend than 93.33% of the companies in the same industry.
Compared to an average S&P500 Dividend Yield of 2.44, CELL pays a better dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.69% |
5.2 History
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
34.37% of the earnings are spent on dividend by CELL. This is a low number and sustainable payout ratio.
DP34.37%
EPS Next 2Y2.47%
EPS Next 3YN/A
BIT:CELL (11/17/2025, 10:05:57 AM)
2.54
-0.01 (-0.39%)
Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupTechnology Hardware & Equipment
GICS IndustryTechnology Hardware, Storage & Peripherals
Earnings (Last)
Earnings (Next)
Inst Owners5.79%
Inst Owner ChangeN/A
Ins Owners19.57%
Ins Owner ChangeN/A
Market Cap55.55M
Revenue(TTM)164.26M
Net Income(TTM)5.65M
Analysts82.86
Price Target4.18 (64.57%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.69% |
Yearly Dividend0.08
Dividend Growth(5Y)N/A
DP34.37%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-12.77%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-28.57%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-11.02%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.77 | ||
| Fwd PE | 5.93 | ||
| P/S | 0.34 | ||
| P/FCF | 3.72 | ||
| P/OCF | 2.74 | ||
| P/B | 0.42 | ||
| P/tB | 1.02 | ||
| EV/EBITDA | 2.97 |
EPS(TTM)0.26
EY10.24%
EPS(NY)0.43
Fwd EY16.87%
FCF(TTM)0.68
FCFY26.86%
OCF(TTM)0.93
OCFY36.54%
SpS7.51
BVpS6.05
TBVpS2.49
PEG (NY)N/A
PEG (5Y)N/A
Graham Number5.95
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.6% | ||
| ROE | 4.27% | ||
| ROCE | 5.04% | ||
| ROIC | 4.42% | ||
| ROICexc | 5.33% | ||
| ROICexgc | 12.93% | ||
| OM | 4.91% | ||
| PM (TTM) | 3.44% | ||
| GM | 40.07% | ||
| FCFM | 9.08% |
ROA(3y)-10.28%
ROA(5y)-5.5%
ROE(3y)-16.94%
ROE(5y)-9.21%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y46.34%
ROICexgc growth 5Y-17.53%
ROICexc growth 3Y77.77%
ROICexc growth 5Y-8.95%
OM growth 3Y35.04%
OM growth 5Y-19.56%
PM growth 3YN/A
PM growth 5Y-23.32%
GM growth 3Y-2.78%
GM growth 5Y-2.73%
F-Score4
Asset Turnover0.76
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.13 | ||
| Debt/FCF | 2.46 | ||
| Debt/EBITDA | 0.81 | ||
| Cap/Depr | 39.19% | ||
| Cap/Sales | 3.28% | ||
| Interest Coverage | 2.77 | ||
| Cash Conversion | 93.13% | ||
| Profit Quality | 264.18% | ||
| Current Ratio | 2.12 | ||
| Quick Ratio | 1.33 | ||
| Altman-Z | 2.34 |
F-Score4
WACC8.75%
ROIC/WACC0.5
Cap/Depr(3y)26.8%
Cap/Depr(5y)35.01%
Cap/Sales(3y)3.22%
Cap/Sales(5y)4.78%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)60.78%
EPS 3YN/A
EPS 5Y-20.43%
EPS Q2Q%-4.76%
EPS Next Y-12.5%
EPS Next 2Y2.47%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)3.54%
Revenue growth 3Y14.1%
Revenue growth 5Y3.18%
Sales Q2Q%-2.91%
Revenue Next Year-5.69%
Revenue Next 2Y-0.6%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y59.25%
EBIT growth 3Y54.08%
EBIT growth 5Y-17%
EBIT Next Year28.5%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y1050.19%
FCF growth 3Y4.84%
FCF growth 5Y6.28%
OCF growth 1Y730.91%
OCF growth 3Y4.12%
OCF growth 5Y1.2%
CELLULARLINE SPA / CELL.MI FAQ
What is the ChartMill fundamental rating of CELLULARLINE SPA (CELL.MI) stock?
ChartMill assigns a fundamental rating of 5 / 10 to CELL.MI.
What is the valuation status of CELLULARLINE SPA (CELL.MI) stock?
ChartMill assigns a valuation rating of 7 / 10 to CELLULARLINE SPA (CELL.MI). This can be considered as Undervalued.
What is the profitability of CELL stock?
CELLULARLINE SPA (CELL.MI) has a profitability rating of 4 / 10.
How financially healthy is CELLULARLINE SPA?
The financial health rating of CELLULARLINE SPA (CELL.MI) is 7 / 10.
What is the expected EPS growth for CELLULARLINE SPA (CELL.MI) stock?
The Earnings per Share (EPS) of CELLULARLINE SPA (CELL.MI) is expected to decline by -12.5% in the next year.